Both letermovir & maribavir can be perpetrator or victim of a drug–drug interaction
🆕️🔥 #CPK
Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir & Maribavir: Guidance for Clinicians #idsky
✨️tables✨️ #bookmark
link.springer.com/article/10.1...
🆕️🔥 #CPK
Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir & Maribavir: Guidance for Clinicians #idsky
✨️tables✨️ #bookmark
link.springer.com/article/10.1...
Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir and Maribavir: Guidance for Clinicians - Clinical Pharmacokinetics
Letermovir and maribavir have demonstrated efficacy in the prevention and treatment, respectively, of immunosuppressed patients with cytomegalovirus (CMV) infection and disease. These patients often h...
link.springer.com
November 15, 2024 at 3:54 PM
Both letermovir & maribavir can be perpetrator or victim of a drug–drug interaction
🆕️🔥 #CPK
Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir & Maribavir: Guidance for Clinicians #idsky
✨️tables✨️ #bookmark
link.springer.com/article/10.1...
🆕️🔥 #CPK
Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir & Maribavir: Guidance for Clinicians #idsky
✨️tables✨️ #bookmark
link.springer.com/article/10.1...
The results of the SOT subgroup analysis of the SOLTICE Phase III RCT (Maribavir vs. IAT) are consistent with those of the overall population. > Effectiveness < Discontinuations. #TxID #IDSky #ViroSky #MedSky pubmed.ncbi.nlm.nih.gov/39613120/
Maribavir for refractory cytomegalovirus infection (with or without resistance) in solid organ transplant recipients: subgroup analysis of the phase 3 randomized SOLSTICE study - PubMed
ClinicalTrials.gov; NCT02931539 DATA AVAILABILITY STATEMENT: The datasets, including the redacted study protocol, redacted statistical analysis plan, and individual participants data supporting the re...
pubmed.ncbi.nlm.nih.gov
November 30, 2024 at 11:35 PM
The results of the SOT subgroup analysis of the SOLTICE Phase III RCT (Maribavir vs. IAT) are consistent with those of the overall population. > Effectiveness < Discontinuations. #TxID #IDSky #ViroSky #MedSky pubmed.ncbi.nlm.nih.gov/39613120/
🔑 Take-home #ESCMIDGlobal2026:
Maribavir shows high real-world effectiveness and good tolerability for CMV in HCT.
⚠️ But resistance, relapse, and data gaps remain
👉 Likely role beyond current indications—needs clearer positioning
Maribavir shows high real-world effectiveness and good tolerability for CMV in HCT.
⚠️ But resistance, relapse, and data gaps remain
👉 Likely role beyond current indications—needs clearer positioning
April 20, 2026 at 11:57 AM
🔑 Take-home #ESCMIDGlobal2026:
Maribavir shows high real-world effectiveness and good tolerability for CMV in HCT.
⚠️ But resistance, relapse, and data gaps remain
👉 Likely role beyond current indications—needs clearer positioning
Maribavir shows high real-world effectiveness and good tolerability for CMV in HCT.
⚠️ But resistance, relapse, and data gaps remain
👉 Likely role beyond current indications—needs clearer positioning
Real-world maribavir data at #ESCMIDGlobal2026:
📊 Mostly used as 2nd/3rd line for CMV
⚠️ Common triggers: refractory infection, cytopenias, renal impairment
🧬 High-risk population: frequent GvHD, varied prophylaxis strategies
🔁 Majority received a single MBV course
📊 Mostly used as 2nd/3rd line for CMV
⚠️ Common triggers: refractory infection, cytopenias, renal impairment
🧬 High-risk population: frequent GvHD, varied prophylaxis strategies
🔁 Majority received a single MBV course
April 20, 2026 at 11:51 AM
Real-world maribavir data at #ESCMIDGlobal2026:
📊 Mostly used as 2nd/3rd line for CMV
⚠️ Common triggers: refractory infection, cytopenias, renal impairment
🧬 High-risk population: frequent GvHD, varied prophylaxis strategies
🔁 Majority received a single MBV course
📊 Mostly used as 2nd/3rd line for CMV
⚠️ Common triggers: refractory infection, cytopenias, renal impairment
🧬 High-risk population: frequent GvHD, varied prophylaxis strategies
🔁 Majority received a single MBV course
Maribavir treated 23 CMV episodes in 20 SOT patients; 61% success, 39% failure, 30% developed resistance, and 36% had recurrence within 4 weeks post-treatment. 🔬💊🦠
Opportunities for antiviral stewardship: a single-center evaluation of maribavir use in solid organ transplant recipients
View
abstract
Objective:Maribavir is a novel antiviral for resistant or refractory (R/R) CMV infection with a favorable safety profile. This report describes institutional use of maribavir in solid organ transplant (SOT) recipients with CMV infection to better understand antiviral stewardship opportunities.Design:Retrospective case series.Setting:Tertiary referral center.Patients/MethodsThis was a single center case series of adult SOT recipients who received maribavir for treatment of R/R CMV infection. The primary outcome was treatment success by 8 weeks. Treatment failure, including development of maribavir resistance, and CMV recurrence were also assessed.Results:Maribavir was used for treatment of 23 episodes of CMV infection in 20 SOT recipients. Treatment success was achieved in 14 (60.9%) episodes in unique patients, with 5/14 patients (35.7%) experiencing CMV recurrence within four weeks of maribavir discontinuation. Treatment failure occurred in 9 (39.1%) of 23 treatment courses, with 6/20 (30%) patients developing treatment-emergent maribavir resistance.Conclusion:Maribavir was a viable option for the management of R/R CMV infection in our real-world single center cohort, as success mirrored that seen in other studies. However, there was a clinically significant portion of patients who failed maribavir or had recurrent CMV. Continued multi-center analysis of maribavir timing, secondary prophylaxis, and patient characteristics that may predict success are warranted to help improve the stewardship of this valuable antiviral.
www.cambridge.org
October 5, 2026 at 11:30 AM
Maribavir treated 23 CMV episodes in 20 SOT patients; 61% success, 39% failure, 30% developed resistance, and 36% had recurrence within 4 weeks post-treatment. 🔬💊🦠
Endpoints matter. #ESCMIDGlobal2026
📌 Primary: CMV resolution at 12 weeks after starting maribavir
📊 Secondary: discontinuation, OS & NRM
⚠️ Failure = viremia progression, rebound, CMV disease, or toxicity
Clear definitions → clearer real-world interpretation of MBV effectiveness 🧬
📌 Primary: CMV resolution at 12 weeks after starting maribavir
📊 Secondary: discontinuation, OS & NRM
⚠️ Failure = viremia progression, rebound, CMV disease, or toxicity
Clear definitions → clearer real-world interpretation of MBV effectiveness 🧬
April 20, 2026 at 11:50 AM
Endpoints matter. #ESCMIDGlobal2026
📌 Primary: CMV resolution at 12 weeks after starting maribavir
📊 Secondary: discontinuation, OS & NRM
⚠️ Failure = viremia progression, rebound, CMV disease, or toxicity
Clear definitions → clearer real-world interpretation of MBV effectiveness 🧬
📌 Primary: CMV resolution at 12 weeks after starting maribavir
📊 Secondary: discontinuation, OS & NRM
⚠️ Failure = viremia progression, rebound, CMV disease, or toxicity
Clear definitions → clearer real-world interpretation of MBV effectiveness 🧬
Real-world maribavir outcomes at #ESCMIDGlobal2026:
📊 ~81% response in PET courses
⚠️ ~17% failure; small proportion with progression/rebound
🧬 Used across complex CMV disease, including end-organ involvement
Promising effectiveness in high-risk patients, but failure& rebound remain key challenges
📊 ~81% response in PET courses
⚠️ ~17% failure; small proportion with progression/rebound
🧬 Used across complex CMV disease, including end-organ involvement
Promising effectiveness in high-risk patients, but failure& rebound remain key challenges
April 20, 2026 at 11:53 AM
Real-world maribavir outcomes at #ESCMIDGlobal2026:
📊 ~81% response in PET courses
⚠️ ~17% failure; small proportion with progression/rebound
🧬 Used across complex CMV disease, including end-organ involvement
Promising effectiveness in high-risk patients, but failure& rebound remain key challenges
📊 ~81% response in PET courses
⚠️ ~17% failure; small proportion with progression/rebound
🧬 Used across complex CMV disease, including end-organ involvement
Promising effectiveness in high-risk patients, but failure& rebound remain key challenges
The aim of this review was to summarize the pharmacokinetic and drug–drug interaction profile of the recently introduced CMV agents letermovir and maribavir #idsky #bookmark #TxID
Both letermovir & maribavir can be perpetrator or victim of a drug–drug interaction
🆕️🔥 #CPK
Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir & Maribavir: Guidance for Clinicians #idsky
✨️tables✨️ #bookmark
link.springer.com/article/10.1...
🆕️🔥 #CPK
Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir & Maribavir: Guidance for Clinicians #idsky
✨️tables✨️ #bookmark
link.springer.com/article/10.1...
Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir and Maribavir: Guidance for Clinicians - Clinical Pharmacokinetics
Letermovir and maribavir have demonstrated efficacy in the prevention and treatment, respectively, of immunosuppressed patients with cytomegalovirus (CMV) infection and disease. These patients often h...
link.springer.com
November 16, 2024 at 8:49 PM
Interesting...
Comparison of on-treatment antiviral resistance rates betw MBV (10%; median 35 d) vs (Val)GCV (2.5%; median 90 days) for CMV infection in HSCT
Treatment response rate was 69.6% (MBV) and 77.4% (V/GCV)
academic.oup.com/jid/article/...
Comparison of on-treatment antiviral resistance rates betw MBV (10%; median 35 d) vs (Val)GCV (2.5%; median 90 days) for CMV infection in HSCT
Treatment response rate was 69.6% (MBV) and 77.4% (V/GCV)
academic.oup.com/jid/article/...
Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection
In a randomized trial of maribavir or valganciclovir for treatment of first-episode cytomegalovirus infection after stem cell transplantation, maribavir re
academic.oup.com
March 20, 2025 at 5:55 PM
Interesting...
Comparison of on-treatment antiviral resistance rates betw MBV (10%; median 35 d) vs (Val)GCV (2.5%; median 90 days) for CMV infection in HSCT
Treatment response rate was 69.6% (MBV) and 77.4% (V/GCV)
academic.oup.com/jid/article/...
Comparison of on-treatment antiviral resistance rates betw MBV (10%; median 35 d) vs (Val)GCV (2.5%; median 90 days) for CMV infection in HSCT
Treatment response rate was 69.6% (MBV) and 77.4% (V/GCV)
academic.oup.com/jid/article/...
Background on maribavir at #ESCMIDGlobal2026:
💊 Oral UL97 inhibitor for R/R CMV post-transplant (EMA approved)
✅ Favorable toxicity profile
⚠️ Resistance in ~7–10%
📉 Still limited real-world data
An important option—but gaps remain in how it performs outside trials 🧬
💊 Oral UL97 inhibitor for R/R CMV post-transplant (EMA approved)
✅ Favorable toxicity profile
⚠️ Resistance in ~7–10%
📉 Still limited real-world data
An important option—but gaps remain in how it performs outside trials 🧬
April 20, 2026 at 11:48 AM
Background on maribavir at #ESCMIDGlobal2026:
💊 Oral UL97 inhibitor for R/R CMV post-transplant (EMA approved)
✅ Favorable toxicity profile
⚠️ Resistance in ~7–10%
📉 Still limited real-world data
An important option—but gaps remain in how it performs outside trials 🧬
💊 Oral UL97 inhibitor for R/R CMV post-transplant (EMA approved)
✅ Favorable toxicity profile
⚠️ Resistance in ~7–10%
📉 Still limited real-world data
An important option—but gaps remain in how it performs outside trials 🧬
Challenging CMV case, transplant ID minds please share thoughts: 57 M renal transplant 10/2023 delayed graft function s/p belatacept 12/2023. CMV viremia 10/2024 w ganciclovir and cidofovir resistance (UL97 (C603W) + UL54 (T503I)) s/p maribavir. Now w CMV viremia again w maribavir resistance (T409m)
December 27, 2024 at 5:28 AM
Challenging CMV case, transplant ID minds please share thoughts: 57 M renal transplant 10/2023 delayed graft function s/p belatacept 12/2023. CMV viremia 10/2024 w ganciclovir and cidofovir resistance (UL97 (C603W) + UL54 (T503I)) s/p maribavir. Now w CMV viremia again w maribavir resistance (T409m)
New Research, oral presentation, Lancet Late Breaker session, #ESCMIDGlobal2026, 20 April
Maribavir for clinically significant cytomegalovirus infection in haematopoietic cell transplant recipients in Europe: a real-world multicentre retrospective registry study
www.thelancet.com/journals/lan...
Maribavir for clinically significant cytomegalovirus infection in haematopoietic cell transplant recipients in Europe: a real-world multicentre retrospective registry study
www.thelancet.com/journals/lan...
Maribavir for clinically significant cytomegalovirus infection in haematopoietic cell transplant recipients in Europe: a real-world multicentre retrospective registry study
The findings of this large real-world study confirm that maribavir is an effective
and well tolerated option for CMV infection and disease in HCT recipients.
www.thelancet.com
April 19, 2026 at 9:24 AM
New Research, oral presentation, Lancet Late Breaker session, #ESCMIDGlobal2026, 20 April
Maribavir for clinically significant cytomegalovirus infection in haematopoietic cell transplant recipients in Europe: a real-world multicentre retrospective registry study
www.thelancet.com/journals/lan...
Maribavir for clinically significant cytomegalovirus infection in haematopoietic cell transplant recipients in Europe: a real-world multicentre retrospective registry study
www.thelancet.com/journals/lan...
@ethanbutol.bsky.social et al: Maribavir is an important therapeutic advancement in the management of R/R CMV. This real world evidence has id'd a number of antiviral stewardship opportunities to improve its use. doi.org/10.1017/ash....
October 5, 2026 at 9:54 PM
@ethanbutol.bsky.social et al: Maribavir is an important therapeutic advancement in the management of R/R CMV. This real world evidence has id'd a number of antiviral stewardship opportunities to improve its use. doi.org/10.1017/ash....
Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase #CMV #MECFS #LongCovid
pubmed.ncbi.nlm.nih.gov/23449792/
pubmed.ncbi.nlm.nih.gov/23449792/
Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase - PubMed
Maribavir (MBV) inhibits Epstein-Barr virus (EBV) replication and the enzymatic activity of the viral protein kinase BGLF4. MBV also inhibits expression of multiple EBV transcripts during EBV lytic in...
pubmed.ncbi.nlm.nih.gov
June 20, 2025 at 3:37 PM
Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase #CMV #MECFS #LongCovid
pubmed.ncbi.nlm.nih.gov/23449792/
pubmed.ncbi.nlm.nih.gov/23449792/
FYIY @italoromeno.bsky.social
« …A further review by the expert panel shortlisted four drugs (famciclovir, tenofovir alafenamide, maribavir and spironolactone) deemed to have the best balance of efficacy, safety and tolerability for use in MS…. »
« …A further review by the expert panel shortlisted four drugs (famciclovir, tenofovir alafenamide, maribavir and spironolactone) deemed to have the best balance of efficacy, safety and tolerability for use in MS…. »
Now THAT is exciting!
"Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach" pubmed.ncbi.nlm.nih.gov/39792343/
"Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach" pubmed.ncbi.nlm.nih.gov/39792343/
Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach - PubMed
Scientific and lived experience expert panel review of anti-EBV therapies selected four candidates with evidence for efficacy against EBV and acceptable safety and tolerability for potential use in ph...
pubmed.ncbi.nlm.nih.gov
January 11, 2025 at 5:40 PM
FYIY @italoromeno.bsky.social
« …A further review by the expert panel shortlisted four drugs (famciclovir, tenofovir alafenamide, maribavir and spironolactone) deemed to have the best balance of efficacy, safety and tolerability for use in MS…. »
« …A further review by the expert panel shortlisted four drugs (famciclovir, tenofovir alafenamide, maribavir and spironolactone) deemed to have the best balance of efficacy, safety and tolerability for use in MS…. »
Late-breaking papers from across Lancet journals on tomorrow, including short-course treatments for UTI, maribavir for CMV, avian flu, precision treatment for TB, and adjunctive betamethasone for mycoplasma.
20 April, 1:30pm, Hall A3-1
#ESCMIDGlobal2026
20 April, 1:30pm, Hall A3-1
#ESCMIDGlobal2026
April 19, 2026 at 9:48 AM
Late-breaking papers from across Lancet journals on tomorrow, including short-course treatments for UTI, maribavir for CMV, avian flu, precision treatment for TB, and adjunctive betamethasone for mycoplasma.
20 April, 1:30pm, Hall A3-1
#ESCMIDGlobal2026
20 April, 1:30pm, Hall A3-1
#ESCMIDGlobal2026
Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: ... #EBV #MECFS #LongCovid
pubmed.ncbi.nlm.nih.gov/39792343/
"expert panel shortlisted four drugs (famciclovir, tenofovir alafenamide, maribavir and spironolactone) ... for use in MS."
pubmed.ncbi.nlm.nih.gov/39792343/
"expert panel shortlisted four drugs (famciclovir, tenofovir alafenamide, maribavir and spironolactone) ... for use in MS."
Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach - PubMed
Scientific and lived experience expert panel review of anti-EBV therapies selected four candidates with evidence for efficacy against EBV and acceptable safety and tolerability for potential use in phase III clinical trials for MS.
pubmed.ncbi.nlm.nih.gov
January 17, 2026 at 2:18 AM
Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: ... #EBV #MECFS #LongCovid
pubmed.ncbi.nlm.nih.gov/39792343/
"expert panel shortlisted four drugs (famciclovir, tenofovir alafenamide, maribavir and spironolactone) ... for use in MS."
pubmed.ncbi.nlm.nih.gov/39792343/
"expert panel shortlisted four drugs (famciclovir, tenofovir alafenamide, maribavir and spironolactone) ... for use in MS."
MARIBAVIR API | MANUFACTURER & BULK SUPPLIER FROM INDIA 🇮🇳
Looking for a trusted source of Maribavir API for antiviral pharmaceutical formulation development, cytomegalovirus (CMV) pharmaceutical research, transplant medicine formulations, pharmaceutical process development, analytical pharmaceutica
Looking for a trusted source of Maribavir API for antiviral pharmaceutical formulation development, cytomegalovirus (CMV) pharmaceutical research, transplant medicine formulations, pharmaceutical process development, analytical pharmaceutica
August 6, 2026 at 12:09 PM
MARIBAVIR API | MANUFACTURER & BULK SUPPLIER FROM INDIA 🇮🇳
Looking for a trusted source of Maribavir API for antiviral pharmaceutical formulation development, cytomegalovirus (CMV) pharmaceutical research, transplant medicine formulations, pharmaceutical process development, analytical pharmaceutica
Looking for a trusted source of Maribavir API for antiviral pharmaceutical formulation development, cytomegalovirus (CMV) pharmaceutical research, transplant medicine formulations, pharmaceutical process development, analytical pharmaceutica
Closing out November's #ISHLTJournalWatch, @sarawinndong.febrilepodcast.com reviews a study from @jhlt.bsky.social on the use of #Maribavir for #CMV infection in SOT recipients—an important addition to the toolbox in treating this infection in #transplant recipients.
#TransplantSky #IDSky #MedSky
#TransplantSky #IDSky #MedSky
December 15, 2025 at 5:37 PM
Closing out November's #ISHLTJournalWatch, @sarawinndong.febrilepodcast.com reviews a study from @jhlt.bsky.social on the use of #Maribavir for #CMV infection in SOT recipients—an important addition to the toolbox in treating this infection in #transplant recipients.
#TransplantSky #IDSky #MedSky
#TransplantSky #IDSky #MedSky
#OTILT I learned that in the SOLSTICE trial, maribavir was more effective and better tolerated than standard therapies for resistant or refractory CMV in transplant patients. @brynnthomas.bsky.social @bwdionne.bsky.social @jeffpears0n.bsky.social
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial - PubMed
Maribavir was superior to IAT for cytomegalovirus viremia clearance and viremia clearance plus symptom control maintained post-therapy in transplant recipients with R/R cytomegalovirus. Maribavir had ...
pubmed.ncbi.nlm.nih.gov
May 29, 2025 at 5:04 PM
#OTILT I learned that in the SOLSTICE trial, maribavir was more effective and better tolerated than standard therapies for resistant or refractory CMV in transplant patients. @brynnthomas.bsky.social @bwdionne.bsky.social @jeffpears0n.bsky.social
🎙️ Episode 7 of Transplant & Oncology ID: Literature Dives is out!
💊 Maribavir for Refractory CMV in SOT
Spotify: open.spotify.com/episode/6xgn...
Apple Podcast: podcasts.apple.com/us/podcast/0...
YouTube: youtu.be/3LhGnw2mEcY
💊 Maribavir for Refractory CMV in SOT
Spotify: open.spotify.com/episode/6xgn...
Apple Podcast: podcasts.apple.com/us/podcast/0...
YouTube: youtu.be/3LhGnw2mEcY
07: Maribavir for Refractory CMV in SOT
Transplant & Oncology ID: Literature Dives · Episode
open.spotify.com
January 9, 2025 at 6:21 PM
🎙️ Episode 7 of Transplant & Oncology ID: Literature Dives is out!
💊 Maribavir for Refractory CMV in SOT
Spotify: open.spotify.com/episode/6xgn...
Apple Podcast: podcasts.apple.com/us/podcast/0...
YouTube: youtu.be/3LhGnw2mEcY
💊 Maribavir for Refractory CMV in SOT
Spotify: open.spotify.com/episode/6xgn...
Apple Podcast: podcasts.apple.com/us/podcast/0...
YouTube: youtu.be/3LhGnw2mEcY
First-trimester exposure to anti-cytomegalovirus medications: a study of the effects of valaciclovir, letermovir and maribavir on early placental development https://www.biorxiv.org/content/10.1101/2025.05.01.651765v1
May 7, 2025 at 8:31 PM
First-trimester exposure to anti-cytomegalovirus medications: a study of the effects of valaciclovir, letermovir and maribavir on early placental development https://www.biorxiv.org/content/10.1101/2025.05.01.651765v1
#Maribavir offers better #cytomegalovirus infections control and fewer toxicities than standard antivirals, but resistance can still emerge, demanding close monitoring.
🆓https://doi.org/10.53855/bjt.v28i1.711_ENG
@scielo.org #BJT #transplant
🆓https://doi.org/10.53855/bjt.v28i1.711_ENG
@scielo.org #BJT #transplant
November 20, 2025 at 4:55 PM
#Maribavir offers better #cytomegalovirus infections control and fewer toxicities than standard antivirals, but resistance can still emerge, demanding close monitoring.
🆓https://doi.org/10.53855/bjt.v28i1.711_ENG
@scielo.org #BJT #transplant
🆓https://doi.org/10.53855/bjt.v28i1.711_ENG
@scielo.org #BJT #transplant
EFFICACY OF MARIBAVIR IN VALGANCICLOVIR-RESISTANT CYTOMEGALOVIRUS RETINITIS
Jonathan C Tsui et al. Retin Cases Brief Rep. 2024
I have a patient on this for different end organ disease. Takeda fairly easy to work with, May have better safety profile than the rest
Jonathan C Tsui et al. Retin Cases Brief Rep. 2024
I have a patient on this for different end organ disease. Takeda fairly easy to work with, May have better safety profile than the rest
January 24, 2025 at 2:28 AM
EFFICACY OF MARIBAVIR IN VALGANCICLOVIR-RESISTANT CYTOMEGALOVIRUS RETINITIS
Jonathan C Tsui et al. Retin Cases Brief Rep. 2024
I have a patient on this for different end organ disease. Takeda fairly easy to work with, May have better safety profile than the rest
Jonathan C Tsui et al. Retin Cases Brief Rep. 2024
I have a patient on this for different end organ disease. Takeda fairly easy to work with, May have better safety profile than the rest
Post transplant viruses in one picture: garbage cans of bones = ganciclovir (myelosuppression), purple UL-92 car + kidney bean = foscarnet (nephrotoxicity), UL-97 Santa with his tongue out = maribavir (dysgeusia).
Make your own at meducationai.com
Make your own at meducationai.com
September 25, 2026 at 2:01 PM
Post transplant viruses in one picture: garbage cans of bones = ganciclovir (myelosuppression), purple UL-92 car + kidney bean = foscarnet (nephrotoxicity), UL-97 Santa with his tongue out = maribavir (dysgeusia).
Make your own at meducationai.com
Make your own at meducationai.com